Abstract 1461P
Background
The optimal duration of ICIs treatment in mNSCLC is debated, arbitrarily fixed to 2 years in the 1st line setting. Unfortunately, pts will mostly relapse months or years after the end of the treatment (EOT). Physicians tend to confirm the partial or complete obtained response before stopping it, by performing 18F-FDG -PET (PET). However, the interpretation of residual fixative areas remains unclear.
Methods
This is a bi-center retrospective study of mNCSLC pts who completed 2 years of ICI, or stopped it due to adverse event without progression and underwent a PET at the EOT. Collected data were: age, smoking status, PDL1 and KRAS status, type and line of treatment, ICI duration.
Results
We enrolled 80 pts who began ICIs between Sept. 2016 and Nov. 2021. Median follow up was 35.9 months. Median age was 61 years (range: 56-69), sex ratio was 1:1, 93.5% were current/former smokers, 87.5% had adenocarcinoma, 54% had PDL1>50%. ICI was given as monotherapy and as first line in 41% and 67.5% of pts respectively. Molecular analysis revealed KRAS G12C mutation in 29% pts. Median ICIs duration was 23.4 months (range: 3-48), 55 pts completed 2 years of ICI, 22 discontinued due to toxicity, 3 for others reasons. The 2-year progression-free survival (PFS) probability was 96% (range:92-100). Median SUVmax was 1.9 (range: 0-17). 55% pts had PET residual fixation (RF): 36% on initial lung tumor, 15% on mediastinal lymph nodes and 5% on extrathoracic sites. 6 pts underwent an excision surgery or a biopsy of a RF: 4 were immune-mediated inflammatory reactions, 2 found the initial histology. 6 pts were locally treated for RF by radiotherapy or surgery. Of the 17 pts who relapsed: 12 had a RF on the PET after ICIs. Conversely, 5/36 pts (14%) without RF relapsed. The presence of a RF was not associated with the PFS in univariable analysis (HR=2.4, 95%CI: 0.8-6.9, P=.121) and after adjusting for duration and type of ICI treatment (HR=1.4, 95%CI: 0.5-4.3, P=.539).
Conclusions
Positive 18F-FDG-PET/CT is not associated with relapse after completion of ICI treatment but has good negative predictive value. Treatment of oligopersistence after partial response to ICI based on PET-scan remains controversial.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sophie Cousin.
Funding
Has not received any funding.
Disclosure
C. Domblides: Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD; Financial Interests, Personal, Other, travel expenses: AstraZeneca, BMS, MSD. All other authors have declared no conflicts of interest.
Resources from the same session
1368P - LUMINATE 102: A real-world study on biomarker testing rates among patients with non-small cell lung cancer (NSCLC) across lines of therapy
Presenter: Charu Aggarwal
Session: Poster session 20
1369P - BrigAlec study: Focus on alectinib efficacy after brigatinib exposure in BrigALK2 study (GFPC 02-2019)
Presenter: Renaud Descourt
Session: Poster session 20
1370P - Efficacy and safety of ensartinib in ALK-positive non-small cell lung cancer patients with brain metastases: A multicenter, open-label, single-arm, phase II study
Presenter: Jianhua Chang
Session: Poster session 20
1371P - First-line alectinib vs. brigatinib in advanced metastatic NSCLC with ALK rearrangement: Real-world data
Presenter: Young Kyung Jeon
Session: Poster session 20
1372P - Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial
Presenter: Ben Solomon
Session: Poster session 20
1373P - Efficacy and safety of taletrectinib in patients (Pts) with ROS1+ non-small cell lung cancer (NSCLC): Interim analysis of global TRUST-II study
Presenter: Maurice Pérol
Session: Poster session 20
1374P - Survival and therapy analysis of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients
Presenter: Moritz Glaser
Session: Poster session 20
1375P - Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data
Presenter: Frans Opdam
Session: Poster session 20
1377P - Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity
Presenter: Xiuning Le
Session: Poster session 20
1378P - Efficacy and safety of tunlametinib (HL-085) combined with vemurafenib in patients with advanced BRAF V600-mutated solid tumors: A multicenter, phase I study
Presenter: Yuan-Kai Shi
Session: Poster session 20